Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
نویسندگان
چکیده
منابع مشابه
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
OBJECTIVE To assess the effectiveness of glatiramer acetate (GA) compared to other multiple sclerosis (MS) therapies in routine clinical practice. MATERIALS AND METHODS Observational cohort study carried out in MS patients treated with GA (GA cohort) or other MS therapies -switched from GA- (non-GA cohort). Study data were obtained through review of our MS patient database. The primary endpoi...
متن کاملTherapy with glatiramer acetate for multiple sclerosis.
BACKGROUND Some clinical data have shown that glatiramer acetate (Copaxone), a synthetic amino acid polymer empirically found to suppress experimental allergic encephalomyelitis (EAE), an animal model of MS, might help improve the outcome of patients with multiple sclerosis (MS). OBJECTIVES We performed a Cochrane review of all randomised, placebo-controlled trials of glatiramer acetate in MS...
متن کاملAdherence to Glatiramer Acetate 40 Mg Versus Oral Disease-Modifying Therapies for Multiple Sclerosis.
GA 40 mg TIW cohort: patients with GA 40 mg on their index dates or who switched to GA 40 mg during post-index and had ≥90 days of post-index after switch; for switchers, the date of the switch to GA 40 mg became the new index date n=232 Oral DMT cohort: patients whose index DMTs were ngolimod, teri unomide, or dimethyl fumarate and who did not switch to GA 40 mg TIW during post-index n=1,547 F...
متن کاملMetabolic response to glatiramer acetate therapy in multiple sclerosis patients
Glatiramer acetate (GA; Copaxone) is a random copolymer of glutamic acid, lysine, alanine, and tyrosine used for the treatment of patients with multiple sclerosis (MS). Its mechanism of action has not been already fully elucidated, but it seems that GA has an immune-modulatory effect and neuro-protective properties. Lymphocyte mitochondrial dysfunction underlines the onset of several autoimmune...
متن کاملRisks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
An understanding of the risks, benefits, and relative value of glatiramer acetate (GA) in multiple sclerosis (MS) has been evolving based on recently completed head-to-head studies: REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease); BEYOND (Betaseron Efficacy Yielding Outcomes of a New Dose); and BECOME (BEtaseron vs COpaxone in Multiple Sclerosis with Triple-Dose Gadolinium and 3-Te...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Brain and Behavior
سال: 2015
ISSN: 2162-3279
DOI: 10.1002/brb3.337